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KEY PO INT S
l High CNS-IPI score
and ABC/unclassiﬁed
COO subtypes were
independent risk
factors for CNS
relapse in DLBCL.
l Combining CNS-IPI
score and COO
improved
identiﬁcation of
DLBCL patients with
different CNS
relapse risks.
Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell
lymphoma (DLBCL). Integrating biomarkers into the CNS–International Prognostic Index
(CNS-IPI) risk model may improve identiﬁcation of patients at high risk for developing
secondary CNS disease. CNS relapse was analyzed in 1418 DLBCL patients treated with
obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone
chemotherapy in the phase 3 GOYA study. Cell of origin (COO) was assessed using gene-
expression proﬁling. BCL2 and MYC protein expression was analyzed by immunohisto-
chemistry. The impact of CNS-IPI, COO, and BCL2/MYC dual-expression status on CNS
relapsewas assessed using amultivariate Cox regressionmodel (data available in n5 1418,
n 5 933, and n 5 688, respectively). High CNS-IPI score (hazard ratio [HR], 4.0; 95%
conﬁdence interval [CI], 1.3-12.3; P5 .02) and activated B-cell‒like (ABC) (HR, 5.2; 95% CI,
2.1-12.9; P 5 .0004) or unclassiﬁed COO subtypes (HR, 4.2; 95% CI, 1.5-11.7; P 5 .006)
were independently associated with CNS relapse. BCL2/MYC dual-expression status did
not impact CNS relapse risk. Three risk subgroups were identiﬁed based on the presence
of high CNS-IPI score and/or ABC/unclassiﬁed COO (CNS-IPI-C model): low risk (no risk factors, n 5 450 [48.2%]), in-
termediate risk (1 factor, n 5 408 [43.7%]), and high risk (both factors, n5 75 [8.0%]). Two-year CNS relapse rates were
0.5%, 4.4%, and 15.2% in the respective risk subgroups. Combining high CNS-IPI and ABC/unclassiﬁed COO improved
CNS relapse prediction and identiﬁed a patient subgroup at high risk for developing CNS relapse. The study was
registered at www.clinicaltrials.gov as #NCT01287741. (Blood. 2019;133(9):919-926)
Reliable identiﬁcation of patients at higher risk of developing
secondary CNS disease is needed. Several clinical prognostic
models have been proposed.1,2,8 The CNS International Prog-
nostic Index (CNS-IPI) model is the most recently developed1
and was built using a large dataset of patients with aggressive
B-cell lymphomas (80% DLBCL), who were enrolled in studies
from the German High-Grade Non-Hodgkin Lymphoma Study
Group and MabThera International Trial, and it was successfully
validated in population-based DLBCL cohorts.9,10 The model
includes the International Prognostic Index (IPI) risk factors
plus involvement of the kidneys and/or adrenal glands.
Introduction
Central nervous system (CNS) relapse is a rare, usually fatal, 
event in diffuse large B-cell lymphoma (DLBCL); median overall 
survival (OS) after its occurrence is 3.5 to 7 months.1,2 Addition 
of rituximab (R) to cyclophosphamide, doxorubicin, vincristine, 
and prednisone (CHOP) signiﬁcantly improves outcomes in 
DLBCL patients3,4; however, its impact on the incidence of 
secondary CNS disease remains unclear, with some studies dem-
onstrating reduced CNS relapse risk in DLBCL patients treated 
with R-CHOP vs CHOP5,6 and others showing similar CNS relapse 
rates.7
2Implementation of biomarkers into the CNS-IPI model may im-
prove identiﬁcation of patients with a high risk for CNS relapse.9
DLBCL represents a biologically heterogeneous disease with
germinal center B-cell–like (GCB) and activated B-cell–like (ABC)
subtypes, each arising from different nonmalignant lymphoid
counterparts.11 DLBCL cell-of-origin (COO) subtypes harbor
speciﬁc genetic abnormalities12-14; for example, GCB DLBCL is
characterized by frequent translocations of the BCL2 gene and
loss of PTEN, whereas ABC DLBCL is characterized by biallelic
loss of the CDKN2A gene, which encodes proteins implicated
in regulation of the cell cycle (p16INK4A) and p53 (ARF) and
chronically active B-cell receptor and NF-kB signaling.12,15-18 The
impact of COO subtype on prognosis has been conﬁrmed
in several studies, with the ABC subtype predicting worse
outcomes.19,20 ABC DLBCL was also shown to be the most
common COO subtype in primary CNS lymphomas.21 Data are
limited on the association of COO subtype with the risk of
secondary CNS disease in DLBCL, with only 1 retrospective
study published to date. Savage et al showed that ABC (or non-
GCB) DLBCL is associated with higher CNS relapse risk.9 In
a multivariate analysis including COO subtype, dual-expression
status of BCL2 and MYC proteins, and CNS-IPI, only high CNS-
IPI score and BCL2/MYC dual expression were signiﬁcantly as-
sociated with CNS relapse risk.9
GOYA is a multicenter randomized phase 3 trial (NCT01287741)
investigating the efﬁcacy and safety of obinutuzumab (G) or R
plus CHOP in patients with previously untreated DLBCL. After
a median observation time of 29.0 months, there were no sig-
niﬁcant differences between G-CHOP and R-CHOP with regard
to progression-free survival (PFS) and OS22; 3-year investigator-
assessed PFS rates were 70% and 67%, respectively. Patients
with GCBDLBCL demonstrated better outcomes than those with
ABC or unclassiﬁed DLBCL, with 3-year PFS rates of 75%, 59%,
and 63%, respectively. Using data from GOYA, we aimed to
evaluate the impact of distinct COO subtypes and dual ex-
pression of BCL2 and MYC proteins on CNS relapse risk.
Methods
Patients, treatment, and clinical assessments
The GOYA study design is described in full elsewhere.22 Patients
had previously untreated histologically documented CD201
DLBCL and an IPI score $ 2, an IPI score of 1 (if age # 60 years,
with or without bulky disease), or an IPI score of 0 (with bulky
disease [1 lesion $ 7.5 cm]). Patients with CNS involvement at
diagnosis were excluded.
Patients received 8 21-day cycles of G or R plus 6 to 8 cycles of
CHOP chemotherapy. CNS prophylaxis with intrathecal chemo-
therapy was recommended to be given according to institutional
practice. No systemic CNS-directed prophylaxis was administered.
Staging investigations included computed tomography scan and
bonemarrow biopsy. Baseline lumbar puncture was recommended
in patients with high-risk disease or with $1 of the following sites
of involvement: paranasal sinuses, testicular, parameningeal, peri-
orbital, paravertebral, or bonemarrow. CNS relapse was diagnosed
according to institutional practice via imaging (magnetic resonance
imaging or computed tomography scan) and/or the presence of
malignant cells in cerebrospinal ﬂuid or affected tissue. The
protocol was approved by the ethics committees of partici-
pating centers. All patients provided written informed consent.
COO, immunohistochemical, and FISH analyses
COO classiﬁcation was performed by a central laboratory based
on gene-expression proﬁling using the NanoString Lymphoma
Subtyping Research-Use-Only assay (NanoString Technologies,
Seattle, WA). Immunohistochemical analysis using BCL2 (clone
124) and MYC (clone Y69) assays (Ventana Medical Systems,
Tucson, AZ) was conducted on slides cut from diagnostic
formalin-ﬁxed parafﬁn-embedded (FFPE) blocks. Cut slide sta-
bility was not considered for selection of tissue sections for
analysis. BCL2 protein expression was assessed according to the
percentage of tumor cells with BCL2 expression and staining
intensity; positivity was deﬁned as moderate or strong staining
in$50%of tumor cells. MYC positivity was deﬁned as expression
in $40% of tumor cells. Immunohistochemical analyses were
conducted in a central laboratory (Hematogenix Laboratory
Services, Chicago, IL). Fluorescence in situ hybridization (FISH)
was performed in a central laboratory (HistoGeneX, Antwerp,
Belgium) on the diagnostic FFPE tissue sections using Vysis LSI
Dual Color, Break Apart probes for BCL2 and MYC rearrange-
ment detection, as previously described.23
Targeted next-generation sequencing
Genomic DNA was extracted from diagnostic FFPE tissue sec-
tions containing $ 20% tumor cells. Samples were submitted to
a central laboratory (Foundation Medicine, Cambridge, MA) for
next-generation sequencing–based genomic proﬁling. Adaptor-
ligated DNA underwent hybrid capture for all coding exons
of 465 cancer-related genes (FoundationOne Heme platform).
Captured libraries were sequenced to a median exon coverage
depth . 5003 (DNA) using Illumina sequencing, and resultant
sequences were analyzed for base substitutions, small insertions
and deletions, copy number alterations (focal ampliﬁcations and
homozygous deletions), and gene fusions/rearrangements, as
previously described.24 Frequent germline variants from the
1000 Genomes Project (dbSNP142) were removed. To maxi-
mize mutation-detection accuracy (sensitivity and speciﬁcity) in
impure clinical specimens, the test was previously optimized and
validated to detect base substitutions at $5% mutant allele fre-
quency, insertions and deletions with $10% mutant allele fre-
quency with $99% accuracy, and fusions occurring within baited
introns/exons with .99% sensitivity.24 Known conﬁrmed somatic
alterations deposited in the Catalogue Of Somatic Mutations In
Cancer (COSMIC v62) are called at allele frequencies$ 1%.25 Next-
generation sequencing–based genomic proﬁling was per-
formed in a subset of patients (617 of 1418) who provided an
optional written informed consent; data that passed the quality
check criteria were evaluable in 499 of 617 patients.
Statistical analysis
The event-speciﬁc cumulative incidence of CNS relapse and
time to CNS relapse were estimated with Kaplan-Meier statistics.
The impact of variables of interest (CNS-IPI, COO, BCL2/MYC
dual-expression status,CDKN2A alteration, and the GOYA study
randomization stratiﬁcation factors [number of planned che-
motherapy cycles, geographical region]) on CNS relapse was
assessed using univariate and multivariate Cox regression
models. In these models, the end point of interest was time to
CNS relapse, deﬁned through themanual review of patients with
3relapse (17 patients treated with chemotherapy only, 6 treated
with chemotherapy and radiotherapy, 4 treated with radio-
therapy only, 6 received no treatment; data not available in
5 patients); 37 of these had radiological signs of CNS relapse
and/or inﬁltrated CSF. In 1 patient, CNS relapse (intraocular)
was diagnosed via cytological evaluation of corpus vitreum. Most
CNS relapses were localized in the brain parenchyma (paren-
chymal only, n5 27 [71.1%]; leptomeningeal only, n5 6 [15.8%];
parenchymal and leptomeningeal, n 5 3 [7.9%]; intraocular,
n 5 1 [2.6%], and data not available, n 5 1 [2.6%]). Median time
to CNS relapse was 8.5 months (range, 0.9-43.5). The majority
(34 [89.5%]) of CNS relapses occurred within 2 years of ran-
domization. The 2-year CNS relapse rate for the entire cohort
was 2.8%. Twenty-four (63%) of 38 patients with CNS relapse
were dead at the time of the analysis; median survival after CNS
relapse was 5.9 months. According to CNS-IPI, 10.5% of patients
with CNS relapse were categorized as low risk, 42.1% were
categorized as intermediate risk, and 47.4% were categorized
as high risk. Two-year CNS relapse rates were 0.8% (95% con-
ﬁdence interval [CI], 0.0-1.9), 1.9% (95% CI, 0.9-2.9), and
8.9% (95% CI, 4.7-12.9) for the low-, intermediate-, and high-risk
CNS-IPI subgroups, respectively (Figure 1A).
Treatment arm and prophylaxis with intrathecal
chemotherapy and CNS relapse risk
The number of CNS relapses was similar in the G-CHOP and
R-CHOP arms (20 vs 18, respectively), with no impact of treat-
ment arm on the incidence of CNS relapse (hazard ratio [HR],
1.13; 95% CI, 0.60-2.15; P 5 .70). Overall, 140 (9.9%) of 1418
patients received intrathecal methotrexate or cytarabine or
Table 1. Key baseline clinical characteristics (CNS-IPI risk factors, CNS-IPI score) of patientswho developed CNS relapse
compared with patients with no CNS relapse and the overall GOYA study population
Characteristic CNS relapse (n 5 38) No CNS relapse (n 5 1380) All patients (N 5 1418)
Age, median (range), y 66.5 (21-81) 61.0 (18-86) 62.0 (18-86)
,60 13 (34.2) 591 (42.8) 604 (42.6)
$60 25 (65.8) 789 (57.2) 814 (57.4)
ECOG PS
0-1 31 (81.6) 1200 (87.0) 1231 (86.9)
2-3 7 (18.4) 179 (13.0) 186 (13.1)
Ann Arbor stage
I or II 4 (10.5) 337 (24.4) 341 (24.1)
III or IV 34 (89.5) 1042 (75.6) 1076 (75.9)
Elevated LDH 26 (68.4) 790 (57.5) 816 (57.7)
Extranodal sites, n
0-1 15 (39.5) 900 (65.2) 915 (64.5)
.1 23 (60.5) 480 (34.8) 503 (35.5)
Involvement of kidneys and/or adrenal glands 11 (28.9) 80 (5.8) 91 (6.4)
CNS-IPI
Low (0-1) 4 (10.5) 275 (20.0) 279 (19.7)
Intermediate (2-3) 16 (42.1) 878 (63.6) 894 (63.0)
High (4-6) 18 (47.4) 227 (16.5) 245 (17.3)
Data are presented as n (%), unless otherwise noted. Data for Eastern Cooperative Oncology Group performance status (ECOG PS) and Ann Arbor Stage were not available in 1 case, and
data on lactate dehydrogenase (LDH) were not available in 5 cases. Differences $ 10% between CNS relapse/no relapse groups are highlighted in bold type.
disease progression or a death event at the time of the pri-
mary analysis cutoff (29 April 2016). The signiﬁcance level of 
5% was used consistently; all tests are 2-sided. No multiplicity 
adjustment was performed in order to avoid loss of power 
due to the low number of events, which is a structural limitation 
of such rare phenomena. R statistical software package ver-
sion 3.4.0,26 together with RStudio version 1.0.153,27 was 
used for all analyses.
Results
Overall, 1418 DLBCL patients, randomized and treated with 
G-CHOP (n 5 706) or R-CHOP (n 5 712) in GOYA, were analyzed 
for CNS relapse occurrence. Baseline characteristics are shown 
in Table 1. According to CNS-IPI score, 279 (19.7%) patients 
were categorized as being at low risk (0-1), 894 (63.0%) patients 
were categorized as being at intermediate risk (2-3), and 
245 (17.3%) patients were categorized as being at high risk (4-6) 
for developing CNS relapse. COO was available for 933 patients, 
of whom 540 (57.9%), 243 (26.0%), and 150 (16.1%) were classiﬁed 
as having GCB, ABC, and unclassiﬁed DLBCL, respectively. Both 
COO and BCL2/MYC protein expression were available in 
688 patients; 295 (42.9%) were BCL2/MYC dual expressers. 
More patients with ABC DLBCL were BCL2/MYC dual expressers 
compared with GCB or unclassiﬁed DLBCL (136 [70.5%] vs 
117 [30.7%] vs 42 [36.8%], respectively; Table 2).
Incidence and outcome of CNS relapse
After a median observation of 29.0 months (interquartile range, 
24.5-37.4), 38 (2.7%) of the 1418 patients developed CNS
4a combination of both as CNS relapse prophylaxis. Within the
low-, intermediate-, and high-risk CNS-IPI groups, 16 (5.7%) of
279, 94 (10.5%) of 894, and 30 (12.2%) of 245 patients received
intrathecal CNS relapse prophylaxis, respectively (supplemental
Table 1, available on the BloodWeb site). Two-year CNS relapse
rates were not different between patients who did or did not
receive CNS relapse prophylaxis (2.8% vs 2.6%). Similarly, the
number of CNS relapses was not different in patients treated or
not with prophylaxis in any of the CNS-IPI categories (0.0% vs
0.9%, 1.3% vs 2.0%, and 8.5% vs 9.0% for the low-, intermediate-,
and high-risk CNS-IPI subgroups, respectively; supplemental
Table 1).
COO and BCL2/MYC dual-expression status and
CNS relapse risk
In patients with COO available (n5 933, 30 CNS-relapse events;
supplemental Table 2), 2-year CNS relapse rates were 1.4% (95%
CI, 0.0-3.2), 2.2% (95% CI, 0.9-3.5), and 9.6% (95% CI, 4.5-14.5)
for the low-, intermediate-, and high-risk CNS-IPI subgroups,
respectively (Figure 1B). On univariate analysis, patients with
ABC and unclassiﬁed DLBCL had signiﬁcantly higher CNS re-
lapse risk than those with GCBDLBCL (HR, 5.2; 95%CI, 2.1-12.7;
P5 .0003; and HR, 4.2; 95%CI, 1.5-11.7; P5 .005; respectively).
Two-year CNS relapse rates were 6.9%, 4.8%, and 1.3% for
patients with ABC, unclassiﬁed, and GCB DLBCL, respectively.
There was no signiﬁcant association between BCL2/MYC dual
expression and the risk for CNS relapse on univariate analysis
(HR, 1.5; 95% CI, 0.7-3.5; P 5 .3196; 2-year CNS relapse rate:
dual-expressers 4.0% vs nondual expressers 2.2%; n 5 688). In
a multivariate analysis of the COO-available population
(n 5 933), ABC subtype (HR, 5.2; 95% CI, 2.1-12.9; P 5 .0004),
unclassiﬁed COO subtype (HR, 4.2; 95% CI, 1.5-11.7; P 5 .006),
and high CNS-IPI (HR, 4.0; 95% CI, 1.3-12.3; P 5 .02) were
associated with greater CNS relapse risk (Table 3). In a multi-
variate analysis of the population with COO and BCL2/MYC
dual-expression status available (n 5 688, 22 CNS-relapse
events; supplemental Table 2), there was no impact of BCL2/
MYC dual expression (HR, 0.8; 95% CI, 0.3-2.1; P5 .69) on CNS
relapse risk, whereas the ABC and unclassiﬁed COO subtypes
remained signiﬁcantly associated with higher CNS relapse risk
(Table 4). In this population, high CNS-IPI score was not sig-
niﬁcantly associated with CNS relapse risk, although a trend for
greater risk was observed (HR, 2.8; 95% CI, 0.8-9.4; P 5 .10).
Overall, 560 (39.5%) of 1418 patients had FISH results available.
Twenty patients (3.6%) harbored both BCL2 and MYC trans-
locations, of whom only 1 patient developed CNS relapse (FISH
data were not included in the statistical analysis because of the
low number of CNS relapses within the double-hit DLBCL).
CNS-IPI andCOOwere combined (1 point for highCNS-IPI, 1 point
for ABC or unclassiﬁed COO) to create a modiﬁed risk-stratiﬁcation
model, CNS-IPI-C. Three CNS-IPI-C subgroups were identiﬁed
as having low (no risk factor, n 5 450 [48.2%]), intermediate
(1 risk factor, n 5 408 [43.7%]), and high (2 risk factors, n 5 75
[8.0%]) CNS relapse risk. The 2-year CNS relapse rates were
Table 2. Key clinical and biomarker characteristics of patients with distinct COO subtypes: GCB, unclassiﬁed, and
ABC DLBCL
Characteristic GCB (n 5 540) Unclassiﬁed (n 5 150) ABC (n 5 243)
Age, median (range), y 62.5 (18-83) 62.0 (21-83) 64.0 (29-86)
,60 228 (42.2) 59 (39.3) 70 (28.8)
$60 312 (57.8) 91 (60.7) 173 (71.2)
ECOG PS
0-1 475 (88.1) 126 (84.0) 209 (86.0)
2-3 64 (11.9) 24 (16.0) 34 (14.0)
Ann Arbor stage
I or II 146 (27.0) 34 (22.7) 52 (21.4)
III or IV 394 (73.0) 116 (77.3) 191 (78.6)
Elevated LDH 308 (57.1) 76 (50.7) 169 (70.4)
Extranodal sites, n
0-1 355 (65.7) 95 (63.3) 158 (65.0)
.1 185 (34.3) 55 (36.7) 85 (35.0)
Involvement of kidneys and/or adrenal glands 36 (6.7) 9 (6.0) 13 (5.3)
CNS-IPI
Low (0-1) 115 (21.3) 29 (19.3) 28 (11.5)
Intermediate (2-3) 335 (62.0) 97 (64.7) 164 (67.5)
High (4-6) 90 (16.7) 24 (16.0) 51 (21.0)
BCL2/MYC dual expression n 5 381 n 5 114 n 5 193
Nodual expressers 264 (69.3) 72 (63.2) 57 (29.5)
Dual expressers 117 (30.7) 42 (36.8) 136 (70.5)
Data are presented as n (%), unless otherwise noted. Data for ECOG PS were not available in 1 case, and data on LDH were not available in 3 cases.
5which were found in 5 (42%) of 12 cases compared with 78 (16.0%)
of 487 cases in the cohort with no CNS relapse. Three of the 5
patients withMYD88mutation had simultaneousCD79Bmutation.
Discussion
The current analysis of GOYA evaluated risk factors associated
with CNS relapse in newly diagnosed DLBCL patients treated
with anti-CD20–based immunochemotherapy (R-CHOP or G-CHOP).
We found no difference in CNS relapse risk between R andG, with
the incidence of CNS relapse similar in both treatment arms and
consistent with the literature.1
With these data, we have provided an independent validation of
the CNS-IPI prognostic model.1 Patients with high CNS-IPI scores
had signiﬁcantly higher risk for CNS relapse than did those with
intermediate or lowCNS-IPI scores. High CNS-IPI scorewas also an
independent risk factor for CNS relapse on multivariate analysis.
The 2-year CNS relapse rate for the high-risk CNS-IPI subgroup in
GOYA (8.9%) was consistent with previous data from Schmitz
et al (10.2%).1 No signiﬁcant difference in the incidence of CNS
relapse was observed between the intermediate- and low-risk
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Figure 1. Risk for CNS relapse by CNS-IPI categories.
(A) Overall GOYA study population (N 5 1418); (B) pop-
ulation with COO data available (n 5 933). EoT, end of
treatment.
0.5% (95% CI, 0.0-1.3), 4.4% (95% CI, 2.2-6.6), and 15.2% (95% CI, 
5.4-24.0), respectively, resulting in a 22-fold higher risk for CNS 
relapse in the high- vs low-risk groups (Figure 2; supplemental 
Table 3).
Mutational proﬁle
Mutational proﬁles were available in 499 of 1418 patients (12 of 
38 patients with CNS relapse; 487 of 1380 without CNS relapse; 
supplemental Table 2). A detailed description of all gene alter-
ations for the patients with CNS relapse is listed in supplemental 
Table 4. CDKN2A was the most frequently (8 of 12; 66.6%) 
altered gene in patients who developed CNS relapse, with 7 cases 
having homozygous deletion of CDKN2A and 1 case harboring 
nonsynonymous CDKN2A mutation; in the population of patients 
without CNS relapse, the prevalence of CDKN2A gene alterations 
was 21.6% (105 of 487). On multivariate analysis, CDKN2A gene 
alterations were associated with higher risk for CNS relapse (HR, 
7.2; 95% CI, 2.1-25.0; P 5 .002), independent of clinical factors. 
The impact of CDKN2A gene alterations on CNS relapse risk was 
weakened after inclusion of COO in the model (HR, 3.6; 95% CI, 
0.93-14.0; P 5 .064). Alterations of genes known to deregulate 
NF-kB signaling were also observed, such as mutations of MYD88,
6CNS-IPI groups. Thismay be due to differences in baseline patient
characteristics in the German High-Grade Non-Hodgkin Lym-
phoma Study Group and MabThera International Trial (testing
cohort for CNS-IPI building) and GOYA study cohorts.1 In the
current study, we conﬁrmed that CNS-IPI is a valuable clinical tool
for identiﬁcation of DLBCL patients with high CNS relapse risk.
Most primary DLBCLs of the CNS resemble the ABC subtype,
suggesting that this biological subtype may be prone to CNS
inﬁltration.21 In the current study, patients with ABC and un-
classiﬁed DLBCL had signiﬁcantly higher CNS relapse risk
compared with those with GCB DLBCL, and, in the multivariate
analysis, COO and a high CNS-IPI score were shown to be in-
dependent risk factors for CNS relapse. Previous data from
Savage et al showed that BCL2/MYC dual expression is associ-
ated with a higher probability of CNS relapse.9 Given the asso-
ciation of the ABC subtypewith dual expression of BCL2 andMYC
proteins, we analyzed whether the higher risk of CNS relapse, at
least in patientswithABCDLBCL, is related to the highprevalence
of BCL2/MYC dual expression. Surprisingly, we did not observe
a higher incidence of CNS relapse in BCL2/MYC dual expressers
compared with nondual expressers in univariate or multivariate
analyses, which may be due to the higher prevalence of BCL2/
MYC dual expression (driven by a high rate of MYC positivity) in
the GOYA study compared with the population examined by
Savage et al (42.1% vs 29.7%, respectively).9,23 The reason for the
high rate of MYC positivity detected in the GOYA study is not
entirely clear. One possible explanation is that the proportion of
patients enrolled with low IPI scores (or low CNS-IPI) was relatively
low, and, therefore, there was a high proportion of high-risk
patients who are more likely to be BCL2/MYC dual expressers.
Larger studies may provide further insight.
Primary CNS lymphomas frequently, if not uniformly, exhibit
biallelic loss of CDKN2A, resulting in cell cycle and p53 pathway
deregulation, or mutations in MYD88 and CD79B, thereby
deregulating NF-kB and B-cell receptor signaling.21,28-31 Al-
though data on the mutational proﬁle were only available for
a limited number of patients, CDKN2A loss and mutation of
MYD88 were the most commonly observed alterations in
patients with CNS relapse. In the multivariate analysis, CDKN2A
loss was associated with a higher risk for CNS relapse, in-
dependent of clinical factors. However, the impact of CDKN2A
loss on the risk of CNS relapse was weaker in a model that
included COO, probably due to the association of CDKN2A
alterations with the ABC subtype, which has been demon-
strated in GOYA, as well as in other studies.32,33 Because of the
limited number of patients with CNS relapse and mutational
proﬁle data available in the GOYA study, further studies are
needed to conﬁrm our hypothesis and to explore the impact of
speciﬁc gene alterations on the risk of CNS relapse, especially
in the context of particular COO subtypes.
Because ABC/unclassiﬁed COO subtypes and high CNS-IPI score
were independent risk factors for CNS relapse, we combined both
factors to improve the risk-stratiﬁcation ability of CNS-IPI, resulting
in a modiﬁed CNS-IPI-C model. CNS-IPI-C allowed the identiﬁ-
cation of 3 subgroups with different 2-year CNS relapse risks. This
incorporation of biomarkers into the CNS-IPI-C model improved
the discrimination of subgroups with a very low and high 2-year
CNS relapse risk compared with the CNS-IPI model (2-year relapse
rate in low- and high-risk subgroups 0.5% vs 1.4% and 15.2% vs
9.6%, respectively). This could help to identify patients who should
undergo a more comprehensive examination of the CNS to ex-
clude asymptomatic CNS lymphoma involvement. It may also
identify patients who could potentially beneﬁt from treatment with
effective prophylaxis to reduce CNS relapse risk.34,35 Last, but not
least, CNS-IPI-C identiﬁes a large subgroup of patients with a very
low risk for CNS relapse who could be spared invasive diagnostic
and prophylactic interventions. However, it must be noted that
CNS-IPI-C needs to be validated in an independent cohort of
DLBCL patients before its potential clinical use.
There is growing evidence that CNS prophylaxis with intrathecal
methotrexate is not sufﬁcient to preventCNS relapse.5,36 Some trials
indicate that high-dose IV methotrexate (3 g/m2) can prevent CNS
relapse37; however, treatment can be associated with signiﬁcant
toxicity, and an acceptable risk-beneﬁt ratio should be carefully
considered.Overall, 9.9%of patients were treatedwith prophylactic
intrathecal chemotherapy in GOYA. We did not observe a signiﬁ-
cant difference in the incidence of CNS relapse in patients who did
or did not receive intrathecal chemotherapy, either in the entire
cohort or in thedifferent risk groups according toCNS-IPI. However,
it must be noted that GOYA was not designed to assess the impact
of CNS prophylaxis on CNS relapse risk. CNS prophylaxis was in-
dicated and administered upon investigator decision, based on
Table 3. Results of multivariate Cox regression analysis
on factors associated with CNS relapse in the COO-
available population (n 5 933)
Factor HR* 95% CI P
CNS-IPI intermediate (vs low) 0.88 0.29-2.74 .8312
CNS-IPI high (vs low) 3.97 1.28-12.33 .0172
ABC COO (vs GCB) 5.18 2.09-12.87 .0004
Unclassiﬁed COO (vs GCB) 4.18 1.50-11.66 .0062
CNS relapses, n 5 30. Factors that were signiﬁcantly associated with greater CNS relapse
risk are highlighted in bold.
*Adjusted for study randomization stratiﬁcation factors (number of planned chemotherapy
cycles, geographic region).
Table 4. Results of multivariate Cox regression analysis
on factors associated with CNS relapse in the COO
and BCL2/MYC dual-expression status–available
population (n 5 688)
Factor HR* 95% CI P
CNS-IPI intermediate (vs low) 0.75 0.23-2.45 .6378
CNS-IPI high (vs low) 2.76 0.81-9.42 .1042
ABC COO (vs GCB) 4.78 1.49-15.29 .0084
Unclassiﬁed COO (vs GCB) 4.24 1.32-13.61 .0151
BCL2/MYC dual expresser
(vs nondual expresser)
0.83 0.34-2.06 .6931
CNS relapses, n 5 22. Factors that were signiﬁcantly associated with greater CNS relapse
risk are highlighted in bold.
*Adjusted for study randomization stratiﬁcation factors (number of planned chemotherapy
cycles, geographic region).
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institutional practice, resulting in heterogeneous schedules and
doses. Randomized clinical trials would be required to deﬁne ap-
propriate CNS prophylaxis in DLBCL.
In conclusion, using the largest prospective dataset of previously
untreated DLBCL with relevant biomarker data to date, we
validated the CNS-IPI clinical prognostic model and demon-
strated that ABC and unclassiﬁed DLBCL are associated with
higher CNS relapse risk compared with GCB DLBCL. Combining
CNS-IPI and COO helped to improve stratiﬁcation of DLBCL
patients with different CNS relapse risks.
Acknowledgments
The authors thank the GOYA study team, investigators, nurses, and 
patients for their contributions and participation.
GOYA was sponsored by F. Hoffmann-La Roche Ltd. with scientiﬁc sup-
port from the Fondazione Italiana Linfomi. Third-party editorial assistance, 
under the direction of M.K., was provided by Lynda McEvoy of Gardiner-
Caldwell Communications and was funded by F. Hoffmann-La Roche Ltd.
The funder was involved in trial design, administration or conduct of 
study procedures, coordination of data collection, and data analysis and 
interpretation. The corresponding authors (M.K. and M.T.) and Roche 
authors (E.A.P., E.S.-G., C.R.B., M.Z.O., G.R.F.-R., and T.N.) had access to 
all data in the study; all other authors had access to the ﬁnal study report.
Authorship
Contribution: M.K., M.Z.O., G.R.F.-R., T.N., and M.T. conceived and 
designed the analysis, and L.H.S., I.B.-B., F.C., J.J., M.M., D.S., U.V., F.Z., 
Q.Z., and M.T. provided study materials or patients; all authors con-
tributed to analyzing and interpreting the data and writing of the 
manuscript and provided ﬁnal approval of the manuscript; and M.K. had 
ﬁnal responsibility for the decision to submit the manuscript for 
publication.
Conﬂict-of-interest disclosure: M.K. was employed by F. Hoffmann-La 
Roche Ltd. during the time of the analysis. L.H.S. has acted as a consultant 
for and received honoraria from Roche/Genentech, Amgen, Janssen, 
Celgene, AbbVie, and Seattle Genetics. I.B.-B. has served as a member of 
the advisory board for F. Hoffmann-La Roche Ltd. M.M. has acted as 
a consultant for F. Hoffmann-La Roche Ltd., Janssen, Sandoz, Takeda, 
Celgene, and Mundipharma; has served as a member of the 
speaker’s
8REFERENCES
1. Schmitz N, Zeynalova S, Nickelsen M, et al.
CNS International Prognostic Index: a risk
model for CNS relapse in patients with diffuse
large B-cell lymphoma treated with R-CHOP.
J Clin Oncol. 2016;34(26):3150-3156.
2. Kanemasa Y, Shimoyama T, Sasaki Y, et al.
Central nervous system relapse in patients
with diffuse large B cell lymphoma: analysis of
the risk factors and proposal of a new prog-
nostic model. Ann Hematol. 2016;95(10):
1661-1669.
3. Coifﬁer B, Lepage E, Briere J, et al. CHOP
chemotherapy plus rituximab compared with
CHOP alone in elderly patients with diffuse
large-B-cell lymphoma. N Engl J Med. 2002;
346(4):235-242.
4. Sehn LH, Donaldson J, Chhanabhai M, et al.
Introduction of combined CHOP plus ritux-
imab therapy dramatically improved outcome
of diffuse large B-cell lymphoma in British
Columbia. J Clin Oncol. 2005;23(22):
5027-5033.
5. Boehme V, Schmitz N, Zeynalova S, Loefﬂer
M, Pfreundschuh M. CNS events in elderly
patients with aggressive lymphoma treated
with modern chemotherapy (CHOP-14) with
or without rituximab: an analysis of patients
treated in the RICOVER-60 trial of the German
High-Grade Non-Hodgkin Lymphoma Study
Group (DSHNHL). Blood. 2009;113(17):
3896-3902.
6. Villa D, Connors JM, Shenkier TN, Gascoyne
RD, Sehn LH, Savage KJ. Incidence and risk
factors for central nervous system relapse in
patients with diffuse large B-cell lymphoma:
the impact of the addition of rituximab to
CHOP chemotherapy. Ann Oncol. 2010;21(5):
1046-1052.
7. Feugier P, Virion JM, Tilly H, et al. Incidence
and risk factors for central nervous system
occurrence in elderly patients with diffuse
large-B-cell lymphoma: inﬂuence of rituximab.
Ann Oncol. 2004;15(1):129-133.
8. Hollender A, Kvaloy S, Nome O, Skovlund E,
Lote K, Holte H. Central nervous system in-
volvement following diagnosis of non-
Hodgkin’s lymphoma: a risk model. Ann
Oncol. 2002;13(7):1099-1107.
9. Savage KJ, Slack GW, Mottok A, et al. Impact
of dual expression of MYC and BCL2 by im-
munohistochemistry on the risk of CNS re-
lapse in DLBCL. Blood. 2016;127(18):
2182-2188.
10. El-Galaly TC, Villa D, Michaelsen TY, et al. The
number of extranodal sites assessed by PET/
CT scan is a powerful predictor of CNS relapse
for patients with diffuse large B-cell lym-
phoma: an international multicenter study
of 1532 patients treated with chemo-
immunotherapy. Eur J Cancer. 2017;75:
195-203.
11. Alizadeh AA, EisenMB, Davis RE, et al. Distinct
types of diffuse large B-cell lymphoma iden-
tiﬁed by gene expression proﬁling. Nature.
2000;403(6769):503-511.
12. Lenz G, Wright GW, Emre NC, et al. Molecular
subtypes of diffuse large B-cell lymphoma
arise by distinct genetic pathways. Proc Natl
Acad Sci USA. 2008;105(36):13520-13525.
13. Pasqualucci L, Trifonov V, Fabbri G, et al.
Analysis of the coding genome of diffuse large
B-cell lymphoma. Nat Genet. 2011;43(9):
830-837.
14. Morin RD, Mendez-Lago M, Mungall AJ, et al.
Frequent mutation of histone-modifying
genes in non-Hodgkin lymphoma. Nature.
2011;476(7360):298-303.
15. Rosenwald A, Wright G, Chan WC, et al;
Lymphoma/Leukemia Molecular Proﬁling
Project. The use of molecular proﬁling to
predict survival after chemotherapy for diffuse
large-B-cell lymphoma. N Engl J Med. 2002;
346(25):1937-1947.
16. Jardin F, Jais JP, Molina TJ, et al. Diffuse large
B-cell lymphomas with CDKN2A deletion
have a distinct gene expression signature and
a poor prognosis under R-CHOP treatment:
a GELA study. Blood. 2010;116(7):1092-1104.
17. Davis RE, Ngo VN, Lenz G, et al. Chronic
active B-cell-receptor signalling in diffuse
large B-cell lymphoma. Nature. 2010;
463(7277):88-92.
18. Davis RE, Brown KD, Siebenlist U, Staudt LM.
Constitutive nuclear factor kappaB activity is
required for survival of activated B cell-like
diffuse large B cell lymphoma cells. J Exp
Med. 2001;194(12):1861-1874.
19. Lenz G, Wright G, Dave SS, et al; Lymphoma/
Leukemia Molecular Proﬁling Project. Stromal
gene signatures in large-B-cell lymphomas.
N Engl J Med. 2008;359(22):2313-2323.
20. Scott DW, Wright GW, Williams PM, et al.
Determining cell-of-origin subtypes of diffuse
large B-cell lymphoma using gene expression
in formalin-ﬁxed parafﬁn-embedded tissue.
Blood. 2014;123(8):1214-1217.
21. Braggio E, Van Wier S, Ojha J, et al. Genome-
wide analysis uncovers novel recurrent alter-
ations in primary central nervous system
lymphomas. Clin Cancer Res. 2015;21(17):
3986-3994.
22. Vitolo U, Trneˇny´ M, Belada D, et al.
Obinutuzumab or rituximab plus cyclophos-
phamide, doxorubicin, vincristine, and
prednisone in previously untreated diffuse
large B-cell lymphoma. J Clin Oncol. 2017;
35(31):3529-3537.
23. Sehn LH, Oestergaard MZ, Trneˇny´ M, et al.
Prognostic impact of Bcl2 and Myc expression
and translocation in untreated DLBCL: results
from the phase III GOYA study. Hematol
Oncol. 2017;35(S2):131-133.
24. Frampton GM, Fichtenholtz A, Otto GA, et al.
Development and validation of a clinical
cancer genomic proﬁling test based on
massively parallel DNA sequencing. Nat
Biotechnol. 2013;31(11):1023-1031.
25. Forbes SA, Bindal N, Bamford S, et al:
COSMIC: mining complete cancer genomes
in the Catalogue of Somatic Mutations in
Cancer. Nucleic Acids Res. 2011;39(database
issue):D945-950.
26. R Core Team. R: A language and environment
for statistical computing. R Foundation for
Statistical Computing. Vienna, Austria; 2017.
https://www.R-project.org/. Accessed 1 June
2018.
27. RStudio Team. RStudio: integrated de-
velopment for R. RStudio, Inc., Boston, MA;
2016. http://www.rstudio.com/. Accessed
1 June 2018.
28. Chapuy B, Roemer MG, Stewart C, et al.
Targetable genetic features of primary
testicular and primary central nervous system
lymphomas. Blood. 2016;127(7):869-881.
29. Cobbers JM, Wolter M, Reifenberger J, et al.
Frequent inactivation of CDKN2A and rare
mutation of TP53 in PCNSL. Brain Pathol.
1998;8(2):263-276.
30. Bruno A, Boisselier B, Labreche K, et al.
Mutational analysis of primary central nervous
system lymphoma. Oncotarget. 2014;5(13):
5065-5075.
31. Yamada S, Ishida Y, Matsuno A, Yamazaki K.
Primary diffuse large B-cell lymphomas of
central nervous system exhibit remarkably
high prevalence of oncogenic MYD88 and
CD79B mutations. Leuk Lymphoma. 2015;
56(7):2141-2145.
32. Bolen C, Klanova M, Trneny M, et al.
Systematic analysis of the prognostic impact
of somatic mutations in diffuse large B-cell
lymphoma (DLBCL) with evaluation of cell-of-
origin dependence: results from the phase 3
GOYA trial in previously untreated DLBCL.
Blood. 2017;130(suppl 1):2729.
33. Reddy A, Zhang J, Davis NS, et al. Genetic and
functional drivers of diffuse large B cell lym-
phoma. Cell. 2017;171(2):481-494.e15.
34. Wilson WH, Bromberg JE, Stetler-Stevenson
M, et al. Detection and outcome of occult
leptomeningeal disease in diffuse large B-cell
lymphoma and Burkitt lymphoma.
Haematologica. 2014;99(7):1228-1235.
35. Muñiz C, Martı´n-Martı´n L, Lo´pez A, et al;
Spanish Group for the Study of Central Ner-
vous System Disease in Non-Hodgkin Lym-
phoma. Contribution of cerebrospinal ﬂuid
sCD19 levels to the detection of CNS lym-
phoma and its impact on disease outcome.
Blood. 2014;123(12):1864-1869.
36. Tai WM, Chung J, Tang PL, et al. Central
nervous system (CNS) relapse in diffuse large
B cell lymphoma (DLBCL): pre- and post-
rituximab. Ann Hematol. 2011;90(7):809-818.
37. Ferreri AJ, Bruno-Ventre M, Donadoni G, et al.
Risk-tailored CNS prophylaxis in a mono-
institutional series of 200 patients with diffuse
large B-cell lymphoma treated in the rituximab
era. Br J Haematol. 2015;168(5):654-662.
